JP2018531625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531625A5 JP2018531625A5 JP2018532523A JP2018532523A JP2018531625A5 JP 2018531625 A5 JP2018531625 A5 JP 2018531625A5 JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018531625 A5 JP2018531625 A5 JP 2018531625A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- recombinant antigen
- antigen binding
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 33
- 108091000831 antigen binding proteins Proteins 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000008499 blood brain barrier function Effects 0.000 claims description 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 229950009904 pritumumab Drugs 0.000 description 4
- -1 scFv Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127980A JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217608P | 2015-09-11 | 2015-09-11 | |
| US62/217,608 | 2015-09-11 | ||
| US201562247490P | 2015-10-28 | 2015-10-28 | |
| US62/247,490 | 2015-10-28 | ||
| PCT/US2016/051128 WO2017044866A2 (en) | 2015-09-11 | 2016-09-09 | Enhanced delivery of drugs to the brain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127980A Division JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531625A JP2018531625A (ja) | 2018-11-01 |
| JP2018531625A5 true JP2018531625A5 (enExample) | 2019-10-17 |
Family
ID=58236547
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532523A Pending JP2018531625A (ja) | 2015-09-11 | 2016-09-09 | 脳への向上した薬物送達の方法 |
| JP2021127980A Pending JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A Active JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A Pending JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127980A Pending JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A Active JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A Pending JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11028155B2 (enExample) |
| EP (2) | EP4548979A3 (enExample) |
| JP (4) | JP2018531625A (enExample) |
| AU (2) | AU2016319133B2 (enExample) |
| CA (1) | CA2998132A1 (enExample) |
| IL (1) | IL257983A (enExample) |
| WO (1) | WO2017044866A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4548979A3 (en) | 2015-09-11 | 2025-07-23 | Nascent Biotech, Inc. | Enhanced delivery of drugs to the brain |
| EP4422683A4 (en) * | 2021-10-29 | 2025-07-30 | Nascent Biotech Inc | KITS AND CONTAINERS FOR THE TREATMENT OF VIMENTIN-EXPRESSING TUMORS |
| US11492394B1 (en) | 2021-10-29 | 2022-11-08 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3223885A1 (de) | 1982-06-26 | 1983-12-29 | Basf Ag, 6700 Ludwigshafen | Makroporoese, hydrophile traeger fuer enzyme |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
| DE69425464T2 (de) | 1993-02-26 | 2001-05-23 | Drug Delivery System Institute, Ltd. | Polysaccharidderivat und wirkstoffträger |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| IL128774A (en) | 1994-03-07 | 2001-05-20 | Dow Chemical Co | Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof |
| JP3631755B2 (ja) | 1994-03-23 | 2005-03-23 | 明治製菓株式会社 | ポリオキシエチレン含有脂質二本鎖誘導体 |
| JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
| US5490840A (en) | 1994-09-26 | 1996-02-13 | General Electric Company | Targeted thermal release of drug-polymer conjugates |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DK2112166T3 (en) | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1286692A4 (en) | 2000-04-25 | 2004-11-17 | Idec Pharma Corp | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| JP2007512846A (ja) * | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| EP1863532A1 (en) | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| EP2428225A3 (en) * | 2006-09-10 | 2012-05-09 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| CN104039809A (zh) * | 2011-10-10 | 2014-09-10 | 希望之城公司 | 中间位和中间位结合抗体及其用途 |
| MY174248A (en) | 2012-04-30 | 2020-04-01 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
| WO2014026054A2 (en) * | 2012-08-10 | 2014-02-13 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
| GB201220242D0 (en) | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| EP4548979A3 (en) | 2015-09-11 | 2025-07-23 | Nascent Biotech, Inc. | Enhanced delivery of drugs to the brain |
-
2016
- 2016-09-09 EP EP24202128.5A patent/EP4548979A3/en active Pending
- 2016-09-09 CA CA2998132A patent/CA2998132A1/en active Pending
- 2016-09-09 JP JP2018532523A patent/JP2018531625A/ja active Pending
- 2016-09-09 EP EP16845201.9A patent/EP3347380B1/en active Active
- 2016-09-09 US US15/261,725 patent/US11028155B2/en active Active
- 2016-09-09 AU AU2016319133A patent/AU2016319133B2/en not_active Ceased
- 2016-09-09 WO PCT/US2016/051128 patent/WO2017044866A2/en not_active Ceased
-
2018
- 2018-03-08 IL IL257983A patent/IL257983A/en unknown
-
2021
- 2021-03-10 US US17/198,029 patent/US20210269513A1/en active Pending
- 2021-08-04 JP JP2021127980A patent/JP2021191269A/ja active Pending
-
2023
- 2023-06-27 JP JP2023104613A patent/JP7361980B2/ja active Active
- 2023-09-07 AU AU2023226718A patent/AU2023226718A1/en not_active Abandoned
- 2023-10-03 JP JP2023172056A patent/JP2024001124A/ja active Pending